Diagnostic Bias in AUS Thyroid Cytology: Role of Perceived Molecular Testing
Diagnostic Cytopathology · 2026
DOI: 10.1002/dc.70092 ↗At a glance
Journal article in Diagnostic Cytopathology, 2026. Written by Olcay Kurtulan and 3 co-authors. Institution: Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey. Major MEDLINE topics: Thyroid Neoplasms, Thyroid Gland, Thyroid Nodule. 29 references.
Abstract (original language)
Background
Atypia of undetermined significance (AUS) represents one of the most controversial diagnostic categories in thyroid cytology, often subject to interpretive bias. This study evaluates whether perceived knowledge of a “positive molecular test” influences the cytologic interpretation of thyroid fine‐needle aspiration (FNA) specimens diagnosed as AUS.
Methods
Twenty thyroid FNA cases diagnosed as AUS with benign histologic follow‐up following thyroidectomy were selected: eight with nuclear atypia (AUS‐N), eight with architectural atypia (AUS‐A), and four with oncocytic features. Representative slides (Papanicolaou and Diff Quik stained smears) were chosen and participants were instructed to evaluate the cases based on morphologic evaluation. Randomly selected 10 cases in two groups were presented to 10 participants as having “positive ThyroSeq test” or “no molecular testing information.” No molecular testing was performed in reality, as the aim was to measure the effects of “perceived positive testing.” Results Analysis of 200 responses showed AUS remained the predominant diagnosis (64%) in both groups. When informed of a presumed positive molecular test, participants were more likely to assign a neoplastic or malignant diagnosis (24% vs. 12%, p = 0.023). This trend was most pronounced in AUS‐N cases (11 vs. 1 reclassified as suspicious/malignant). For AUS‐A cases, more were reclassified as follicular neoplasm under presumed molecular positivity (12 vs. 8). Overall interobserver agreement was poor (Fleiss' kappa = 0.046).
Conclusion
Awareness of a presumed positive molecular test result increases the likelihood of pathologists reclassifying AUS cases as suspicious or malignant. Recognizing and mitigating such cognitive biases is critical for maintaining diagnostic objectivity and ensuring accurate, evidence‐based cytologic evaluation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Department of Pathology and Laboratory Medicine, Loyola University Healthcare System, Maywood, Illinois, USA.
- Department of Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
ORCID profiles: Olcay Kurtulan, Güliz A Barkan
Cite
APA
Kurtulan, O., Kilic, I., Avcı, H., & Barkan, G. A. (2026). Diagnostic Bias in AUS Thyroid Cytology: Role of Perceived Molecular Testing. Diagnostic Cytopathology. https://doi.org/10.1002/dc.70092
Vancouver
Kurtulan O, Kilic I, Avcı H, Barkan GA. Diagnostic Bias in AUS Thyroid Cytology: Role of Perceived Molecular Testing. Diagnostic Cytopathology. 2026. doi:10.1002/dc.70092
BibTeX
@article{Kurtulan2026,
author = {Kurtulan, Olcay and Kilic, Irem and Avcı, Hanife and Barkan, Güliz A},
title = {Diagnostic Bias in AUS Thyroid Cytology: Role of Perceived Molecular Testing},
journal = {Diagnostic Cytopathology},
year = {2026},
doi = {10.1002/dc.70092}
}
EUVIMED